Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parnax LabBOM:506128 -2.32%69 Days Inventory is 76.07 as of Mar. 2026, which is 28% above its 10-year median of 59.55. GuruFocus rates BOM:506128 with a GF Score™ of 69/100 and a GF Value™ of ₹149.14 (Fairly Valued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Parnax Lab ranks better than 86.89% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Parnax Lab's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹362 Mil. Parnax Lab's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹435 Mil.
Hence, Parnax Lab's Days Inventory for the
three
months ended in Mar. 2026 was 76.07.
The historical rank and industry rank for Parnax Lab's Days Inventory or its related term are showing as below:
BOM:506128'
s Days Inventory Range Over the Past 10 Years
Min: 39.25 Med: 59.55 Max: 105.88
Current: 78.76
During the past 13 years, Parnax Lab's highest Days Inventory was 105.88. The lowest was 39.25. And the median was 59.55.
BOM:506128's Days Inventory is ranked better than 86.89% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:506128: 78.76
Parnax Lab's Days Inventory
declined
from Mar. 2025 (89.47) to Mar. 2026 (76.07).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Parnax Lab's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.20.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parnax Lab's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.52.
Parnax Lab (BOM:506128) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Parnax Lab's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Parnax Lab's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Parnax Lab Days Inventory Related Terms
Parnax Lab Days Inventory Historical Data
* Premium members only.
The historical data trend for Parnax Lab's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parnax Lab Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's Days Inventory distribution charts can be found below:
* The bar in red indicates where Parnax Lab's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parnax Lab (BOM:506128) has a Days Inventory of 76.07 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Parnax Lab and its competitors. This is 28% above median its historical median of 59.55. Over the past decade, Parnax Lab's Days Inventory has ranged from 39.25 to 105.88. According to the industry distribution chart, Parnax Lab ranks #121 out of 923 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is Parnax Lab's Days Inventory too high?
Parnax Lab's current Days Inventory of 76.07 is 28% above median its 10-year median of 59.55. Over the past 10 years, this metric has ranged from a low of 39.25 to a high of 105.88. The Drug Manufacturers industry median Days Inventory is 164.87. Parnax Lab's value of 76.07 is 53.9% below this industry median. Based on the distribution chart, Parnax Lab ranks #121 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Parnax Lab has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Parnax Lab's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parnax Lab ranks #121 out of 923 companies for Days Inventory. This places Parnax Lab in the top 13% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.87. Parnax Lab's value of 76.07 is 53.9% below this benchmark. Historically, Parnax Lab's own Days Inventory has ranged from 39.25 to 105.88 over the past decade. While the company's 10-year median is 59.55 vs. the industry median of 164.87, Parnax Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parnax Lab's current Days Inventory of 76.07 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Parnax Lab and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parnax Lab's current Days Inventory is 76.07, which is 28% above median its own 10-year median of 59.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parnax Lab stock overvalued right now?
Based on GuruFocus' analysis, Parnax Lab (BOM:506128) is currently considered Fairly Valued. The stock's GF Value™ is ₹149.14, compared to a current price of ₹135.00 — trading 9.5% below its estimated fair value. The current Days Inventory is 76.07, which is 28% above median its 10-year median of 59.55 and 53.9% below the Drug Manufacturers industry median of 164.87. Parnax Lab's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Parnax Lab (BOM:506128), the current Days Inventory is 76.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parnax Lab (BOM:506128) Overvalued in 2026?
Based on GuruFocus' analysis, Parnax Lab stock appears to be undervalued.
The current stock price of ₹135.00 is trading 9.5% below its estimated GF Value™ of ₹149.14.
GuruFocus considers Parnax Lab to be Fairly Valued.
Key valuation signals for BOM:506128:
Days Inventory: 76.07 (28% above median its 10-year median of 59.55)
GF Value™: ₹149.14 vs. price of ₹135.00 (9.5% below fair value)
Industry Position: 53.9% below the Drug Manufacturers median (#121 of 923)
No single metric tells the full story. See the BOM:506128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
69GF Score
Get the complete analysis for BOM:506128
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506128 has been successfully added to your 
